Evidence map›Paper›PMID 37188175›Full record

ArticleFrontiers in oncology2023

Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost.

Agnieszka Skrobala, Marta Kruszyna-Mochalska, Kinga Graczyk, Adam Ryczkowski, Magdalena Fundowicz, Piotr Milecki, Julian Malicki

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Agnieszka SkrobalaDepartment of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Marta Kruszyna-MochalskaDepartment of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Kinga GraczykDepartment of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.
Adam RyczkowskiDepartment of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland.
Magdalena FundowiczDepartment of Radiation Oncology I, Greater Poland Cancer Centre, Poznan, Poland.
Piotr MileckiDepartment of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Julian MalickiDepartment of Electroradiology, Poznan University of Medical Science, Poznan, Poland.
Poznan University of Medical Sciences · PLGreater Poland Cancer Center · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: In the treatment of prostate cancer with radiation therapy, the addition of a simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL) may improve local control. In this study, we aimed to determine the optimal radiation strategy in a phantom model of prostate cancer using volumetric modulated arc therapy for stereotactic body radiotherapy (SBRT-VMAT) with a SIB of 1-4 DILs. Methods: We designed and printed a three-dimensional anthropomorphic phantom pelvis to simulate individual patient structures, including the prostate gland. A total of 36.25 Gy (SBRT) was delivered to the whole prostate. The DILs were irradiated with four different doses (40, 45, 47.5, and 50 Gy) to assess the influence of different SIB doses on dose distribution. The doses were calculated, verified, and measured using both transit and non-transit dosimetry for patient-specific quality assurance using a phantom model. Results: The dose coverage met protocol requirements for all targets. However, the dose was close to violating risk constraints to the rectum when four DILs were treated simultaneously or when the DILs were located in the posterior segments of the prostate. All verification plans passed the assumed tolerance criteria. Conclusions: Moderate dose escalation up to 45 Gy seems appropriate in cases with DILs located in posterior prostate segments or if there are three or more DILs located in other segments.

Indexed as

DILpatient-specific quality assurancephantom modelSBRT-SIBtransit and non-transit dosimetryVMAT

Identifiers

PMID37188175
PMCPMC10175813
OpenAlexW4367318038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.